Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug... (cancerimmune system disorders and ophtha...)

Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Date:8/19/2007

cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and the potential therapeutic and commercial potential of LX1031. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
3. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/20/2013)... 2013 A medical diagnostic technology that experts ... and on Earth was inducted recently in the Space ... assures high quality, secure handling and transmission of diagnostic ... those used in hospitals and medical offices. Real time ... of choice for human space missions. Tests have shown ...

(Date:5/20/2013)... CARLSBAD, Calif. , May 20, 2013 ... today announced that its Applied Biosystems™ 3500 Dx and ... Federal Commission for Protection against Health Risks in ... marks a major extension of Life Technologies, capabilities to ... America with Sanger -based ...

(Date:5/20/2013)... , LONDON , BERLIN ... 20, 2013 Arthroscopy Devices ... and Preference for Minimally Invasive Procedures to Drive Future ... market trends for the six arthroscopy device market segments: ... implants, arthroscopy radio frequency systems, and arthroscopy visualization systems. ...

Breaking Medicine Technology:Wyle Aided System Gets Named to Space Technology Hall of Fame 2 Wyle Aided System Gets Named to Space Technology Hall of Fame 3 Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2 Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3 Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2 Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3 Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4

[0] Wyle Aided System Gets Named to Space Technology Hall of Fame [0] Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico [0] Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth

... Nov. 11 WellTek/MedX Group, health, fitness and wellness ... corporate reorganization to facilitate becoming an SEC reporting company. ... Inc. merged into a wholly owned subsidiary of an ... subsequently changed its name to WellTek Incorporated. As ...

... (NYSE: CRY ), an implantable biological medical device ... Anderson, president and chief executive officer of CryoLife, Inc., is ... Annual Healthcare Conference on Wednesday, November 18, 2009 at 1:15 ... may be accessed through its Web site, www.cryolife.com ...

Cached Medicine Technology:WellTek/MedX Group Completes Major Reorganization 2 CryoLife to Present at Upcoming Investor Conferences in New York 2

WellTek/MedX Group Completes Major Reorganization CryoLife to Present at Upcoming Investor Conferences in New York

(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 ... protecting the rights of victims injured by defective drugs, ... Dakota man who alleges that use of the diabetes ... The suit was filed on April 30, 2013, in ... Louisiana (Case No. 6:13-cv-0888), where it is one of ...

(Date:5/20/2013)... May 20, 2013 According to a May ... at Indoor Tanning Salons,” tanning salons in the ... Food and Drug Administration wants to see cancer warnings on ... minimum age floor of eighteen for the use of indoor ... about melanoma, which has become increasingly common over the last ...

(Date:5/20/2013)... 2013 The Environmental Design ... dozens of continuing education credit opportunities for design ... of Architects Continuing Education System (AIA/CES), the Landscape ... Interior Design Continuing Education Council (IDCEC). EDRA44Providence ... 2013 at the Omni Providence Hotel in Providence, ...

(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...

(Date:5/20/2013)... The judge overseeing pretrial proceedings in the federal consolidation ... lawyers to be included in a plaintiffs’ leadership committee, ... the judge’s request, noting that its lawyers can ... Mirena side effects and how to file a lawsuit. ... some female lawyers to the committee. This followed requests ...

Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2 Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2 Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2

[0] Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits [0] EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City [0] Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP

... someday help control anxiety, experts say, , , FRIDAY, May 15 ... anxiety isn,t something associated with heights, a job interview or ... state of worry and tension that affects twice as many ... slowly eroding their quality of life. , But a new ...

... ORLANDO A pill used for nerve pain offers women ... 45th Annual Meeting of the American Society of Clinical ... hot flash severity and frequency about 20 percent more than ... the same benefit as gabapentin, an older, related drug, as ...

... in GI and Endoscopy Nursing at SGNA 36th Annual ... Nurses and Associates, Inc. (SGNA) is proud to honor ... awards that recognize their dedication to the field and ... distinguished awards represent the best in GI and endoscopy ...

... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...

... 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality, pharmaceutical grade,glucose products in China, ... of fiscal 2009 ended March 31, 2009. , ... has impacted our operations thus far in,fiscal year ...

... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...

Fear Response May Stem From Protein in Brain Mayo Clinic researchers say agent provides treatment option for women with hot flashes SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional

... Blind Performance Specimens are intended for ... handling and transportation guidelines, including chain ... Testing Programs regulated by the Substance ... (SAMHSA), Health and Human Services Department ...

Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....

Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates....

Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...

Medicine Products:

Blind Performance Specimens Lyphochek Hemoglobin A1C Linearity Set Liquichek Sedimentation Rate Control Liquichek Reticulocyte Control